Clinical Trial Update: Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the safety and immunogenicity of Merck's ZOSTAVAX vaccine produced with an Alternative Manufacturing Process (AMP); results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Herpes Zoster, Shingles | Phase 3 | Status: COMPLETED | Results posted: 2013-07-03